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Background: Recent findings indicate that exosomes released from cancer cells contain microRNAs (miRNAs) that
may be delivered to cells of tumor microenvironment.
Results: To elucidate whether miRNAs secreted from chronic myelogenous leukemia cells (CML) are shuttled into
endothelial cells thus affecting their phenotype, we first analysed miRNAs content in LAMA84 exosomes. Among
the 124 miRNAs identified in LAMA84 exosomes, we focused our attention on miR-126 which was found to be
over-overexpressed in exosomes compared with producing parental cells. Transfection of LAMA84 with Cy3-labelled
miR-126 and co-culture of leukemia cells with endothelial cells (EC) confirmed that miR-126 is shuttled into HUVECs.
The treatment of HUVECs with LAMA84 exosomes for 24 hours reduced CXCL12 and VCAM1 expression, both at
the mRNA and protein level, and negatively modulated LAMA84 motility and cells adhesion. Transfection in HUVECs
of miR-126 inhibitor reversed the decrease of CXCL12 and restored the motility and adhesion of LAMA84 cells while
the over-expression of miR-126, showed opposite effects.
Conclusion: Our results show that the miR-126 shuttled by exosomes is biologically active in the target cells, and
support the hypothesis that exosomal miRNAs have an important role in tumor-endothelial crosstalk occurring in
the bone marrow microenvironment, potentially affecting disease progression.
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Chronic myeloid leukemia is a myeloproliferative dis-
order that originates from a hematopoietic stem cell or a
multipotent progenitor. The hallmark of the disease is
the presence of the Philadelphia (Ph) chromosome gen-
erated from a reciprocal t(9:22) (q34:q11) translocation
that creates the BCR-ABL oncogene encoding a chimeric
oncoprotein with constitutive tyrosine kinase activity [1].
Several mechanisms are involved in the malignant trans-
formation driven by Bcr–Abl [2] and these altered sig-
nalling pathways are ultimately responsible for the
increased proliferation, altered cell adhesion, inhibition
of apoptosis and enhanced bone marrow angiogenesis* Correspondence: riccardo.alessandro@unipa.it
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unless otherwise stated.observed during the progression of the disease [3]. A
number of recent studies have described exosomes as new
players in modulating the tumour microenvironment,
promoting angiogenesis, tumour development and for-
mation of metastasis [4]. We recently showed that CML
cell lines such as LAMA84 and K562 and Imatinib-
resistant LAMA84 cells as well as patient’s leukemic
blasts, release exosomes that directly affect endothelial
cells, thus modulating the process of neovascularization.
Specifically, the stimulation of HUVECs with LAMA84
exosomes activates signal transduction pathways leading
to the release of IL 8 and the induction, in vitro and
in vivo, of an angiogenic phenotype [5-7]. A topic of
particular interest is that exosomes contain miRNAs
that can be shuttled to target cells and modulate their
behavior. MiRNAs are small (19–22 nucleotides) noncod-
ing RNA molecules that bind to partially complementaryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion inhibition [8]. It has been demonstrated that exo-
somes released by leukemia cells mediate the crosstalk
between leukemia cells and endothelial cells. In particular
exosomes released from K562 cells contain miR-210 and
miR-92a which enhanced endothelial cell migration and
tube formation [9,10].
Using miRNA array and miScript Primer Assay we
found that miR-126 was expressed 6 fold greater in
LAMA84 exosomes compared with cells. Interestingly,
miR-126 has been found to be involved in angiogenesis by
targeting sprouty‑related protein with an enabled/VASP
homology 1 domain (SPRED1) and phosphoinositide‑3‑ki-
nase regulatory subunit 2 (PIK3R2), known negative regu-
lators of VEGF signaling [11].
Moreover, miR‑126 inhibits both CXCL12 and vascu-
lar cell adhesion molecule 1 (VCAM1) expression, which
are involved in leukocyte homing in bone marrow and
adhesion to ECs respectively [12,13].
CXCL12 is a chemokine that binds specifically to the
G-protein coupled receptor, CXCR4. In vitro and in vivo
studies have clearly demonstrated a key role of CXCR4/
CXCL12 interactions in the migration of cells within tis-
sues and, more specifically, in the homing of immune
cells in the bone marrow [14]. During CML progression,
a modulation of CXCR4/CXCL12 chemotaxis gradient
may contribute to the mobilization of leukemic cells into
the circulation [15,16].
VCAM1 is a cell-cell adhesion molecules constitutively
expressed on endothelial cells in bone marrow (BM) ve-
nules; which has been found to play an important role in
the homing of Philadelphia positive CD34+ to the BM
[17]. Interestingly, previous works have demonstrated
that CXCL12 up-regulates VCAM1 adhesive function in
myeloma cells and chronic lymphocytic leukemia B cells,
and that modulation of this pathway can play important
roles in the trafficking and localization of malignant cells
to the bone marrow [17,18].
In this study, we show that miR-126 transferred to
endothelial cells via LAMA84 exosomes directly targets
the 3’ UTR of CXCL12 and VCAM1 mRNA, significantly
down-regulating the expression and function of both
proteins. This modulation could have important conse-
quences in CML progression.
Results
HUVECs internalize LAMA84 exosomes
LAMA84 cells release into the culture medium vesicles
that we isolated, purified on a sucrose gradient and char-
acterized as exosomes as previously demonstrated from
our group [7].
The ability of LAMA84 exosomes to be transferred to
endothelial cells was studied by examining the uptake of
isolated exosomes labeled with PKH-26. HUVECs treatedwith LAMA84 exosomes, internalized exosomes in a time
and dose-dependent manner (Figure 1, panel a). Exosomes
rapidly entered into the HUVECs at 37°C and localized in
the perinuclear compartment after 4 hours of incubation
(Figure 1, panel a). However, the uptake of exosomes in
HUVECs was blocked by incubation at 4°C (Figure 1,
panel a) or by treatment of endothelial cells with 50 μM
EIPA (Figure 1, panel b), a known blocker of macropino-
cytosis [19] thus confirming that exosomes internalization
was mediated by endocytosis in an energy-dependent
process, as previously described [12,20]. Semi-quantitative
analysis of PKH-26-exosomes fluorescence intensity in
the cytoplasm of HUVECs is shown in Additional file 1:
Figure S1.
LAMA84 exosomes transport miRNAs
Analysis with Bioanalyzer of LAMA84 exosomal RNAs
showed the presence of abundant short RNAs (data not
shown) as previously described [21]. In order to deter-
mine the exosomes miRNA profiles and to identify dif-
ferentially expressed miRNAs in exosomes versus
LAMA84 cells, a TaqMan low-density miRNA array was
done. We identified 200 miRNAs, among these, 76 miR-
NAs were only expressed in LAMA84 cells (38%), 18
miRNAs were exclusively expressed in LAMA84 exo-
somes (9%) and 106 miRNA were differentially expressed
between LAMA84 exosomes and LAMA84 cells (53%)
(Additional file 2: Figure S2, a). These results showed that
LAMA84 exosomes transported 124 miRNAs and suggest
a sorting mechanism of miRNAs in exosomes. We used
miR-18b for miRNAs normalization it showed no vari-
ation between cells and exosomes, though comparable re-
sults were obtained using RNU6, a known small nuclear
RNA used for miRNAs normalization. We identified 89
miRNAs with increased level (FC > 2) and 17 miRNAs
with decreased level (FC < 0.5) in LAMA84 exosomes ver-
sus LAMA84 cells (Additional file 2: Figure S2, b). Be-
cause we had previously showed that LAMA84 exosomes
stimulate in vitro and in vivo angiogenesis, we focused our
attention on angiogenic miRNAs, and particularly on
miR-126 which was enriched in LAMA84 exosomes with
respect to LAMA84 cells as demonstrated by miRNAs ex-
pression profile and single real time quantitative assay
(Additional file 2: Figure S2, c).
Exosome-mediated shuttling of miR-126 into endothelial
cells
In order to demonstrate the uptake of miR-126 in
HUVECs, we treated endothelial cells with 20–50 μg/ml of
LAMA84 exosomes and, after 24 h, analyzed the expres-
sion levels of miR-126 in HUVECs. As shown in Figure 2a,
miR-126 was up-regulated in a dose-dependent manner
compared with untreated HUVECs. In order to exclude
the possibility that LAMA84 exosomes could induce the
Figure 1 HUVECs internalize LAMA84 exosomes. a: Analysis at confocal microscopy of HUVECs treated, for 1 hour and 4 hours, with 20 μg/ml
(Exo 20 μg/ml) and 50 μg/ml (Exo 50 μg/ml) of LAMA84 exosomes, compared with untreated HUVECs (Control). HUVECs were stained with
phalloidin Alexa Fluor (green), nuclear counterstaining was performed using Hoescht (blue), exosomes were labelled with PKH26 (red). To evaluate
whether exosomes uptake was mediated by endocytosis in an energy-dependent process, HUVECs treated with 20 μg/ml (Exo 20 μg/ml) and
50 μg/ml (Exo 50 μg/ml) of LAMA84 exosomes were incubated at 4°C, for 1 hour and 4 hours and compared with untreated HUVECs. b: Analysis
at confocal microscopy of HUVECs treated, for 1 hour, with 50 μg/ml of exosomes (Exo 50 μg/ml) and EIPA (50 μM), compared with control cells
(Control). Scale bar = 10 μm.
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tified the levels of precursor miR-126 (pre-miR-126) in
HUVECs with Real Time PCR. As shown in Figure 2b, we
found no statistically significant difference of pre-miR-126
expression level after treatment of EC with 20–50 μg/ml of
exosomes. To visualize the transfer of exosomal miR-126
into HUVECs, LAMA84 cells were transfected with Cy3-
labeled pre-miR-126 and co-cultured with HUVECs in
transwells. After 24 hours of co-culture, Cy3-miR-126 sig-
nals were detected in the cytoplasm of HUVECs (Figure 2
panel c). We did not observe red fluorescence in HUVECs
cocoltured with untransfected LAMA84 cells (Figure 2
panel c: Control) or treated with 1–5 μM of GW4869, a
specific neutral sphingomyelinase (nSMase) 2 inhibitor alsoknown as an inhibitor of exosome release (Figure 2 panel
c) [22]. The semi-quantitative analysis of miR-126-Cy3
fluorescence intensity in the cytoplasm of HUVECs is
shown in Additional file 2: Figure S2 d.
Exosomal miR-126 targets CXCL12 and VCAM 3’-UTR
mRNA in HUVECs
miRNA target prediction algorithms indicate that
CXCL12 and VCAM1 are predictive targets of miR-126.
Recent studies report that endothelial miR-126 targets
CXCL12 and represses VCAM1 expression in vascular
cells [12]. We confirmed that exosomal miR-126 binds
to CXCL12 3’UTR mRNA using a Firefly/Renilla Duo-
Luciferase reporter vector (pEZX-MT01), where the 3’
Figure 2 Exosomes shuttle miR-126 in HUVECs. a: MiR-126 expression in HUVECs treated with different amounts of LAMA84 exosomes.
miR-126 expression levels in HUVECs treated with 20 and 50 μg/ml of LAMA84 exosomes for 24 hours were determined by quantitative Real
time PCR analysis. Values are the mean ± SD of 3 independent experiments *p ≤ 0.05. b: Pre-miR-126 expression in HUVECs treated with different
amounts of LAMA84 exosomes. Pre-miR-126 expression levels in HUVECs treated with 20 and 50 μg/ml of LAMA84 exosomes for 24 hours were
determined by quantitative Real time PCR analysis. c: Localization of exosomal miR-126 into HUVECs. HUVECs were co-cultured with LAMA84/Cy3-
miR-126 cells using Transwells. In Red is shown Cy3-miR-126 in the cytoplasm of HUVECs (miR-126/Cy3), nuclear counterstaining was done with
Hoescht (blue). As a negative control, HUVECs were co-cultured with untrasfected LAMA84 (Control). HUVECs were also cocoltured with LAMA84/
Cy3-miR-126 cells treated with 1 μM (miR-126/Cy3 + 1 μM GW4869) and 5 μM (miR-126/Cy3 + 5 μM GW4869) of GW4869.
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luciferase gene (Figure 3a) (CXCL12-pEZX). When
HUVECs transfected with reporter plasmid were incubated
with 50 μg/ml of LAMA84 exosomes, the firefly luciferase
activity was reduced by 50% compared with untreated
HUVECs (Figure 3b) transfected with CXCL12-pEZX.
Overexpression of miR-126, by transfection of miR-126
mimic into HUVECs containing CXCL12-pEZX, reduced
the activity of firefly luciferase by approximately 45%
compared with untransfected HUVECs, similarly to
LAMA84 exosomes treatment. In contrast, luciferaseactivity increased when HUVECs containing CXCL12-
pEZX were transfected with miR-126 inhibitor. The
treatment of CXCL12-pEZX transfected HUVECs with
LAMA84 exosomes, after silencing of miR-126, abolished
the increased luciferase activity (Figure 3b). Similar results
were obtained when HUVECs were transfected with a Fire-
fly/Renilla Duo-Luciferase reporter vector (pEZX-MT01)
containing upstream of luciferase gene the VCAM1 3’UTR
fragment (Figure 3c-d). These data indicate that exogenous
miR-126 transported via exosomes may function like an
endogenous miRNA in HUVECs.
Figure 3 MiR-126 targets CXCL12 and VCAM1. a: Schematic representation of matching sequence between CXCL12 3’UTR mRNA and miR-126.
b: Luciferase activity of HUVECs transfected with reporter plasmid (CXCL12-pEZX), treated with LAMA84 exosomes and/or contrasfected
with miR-126 inhibitor or miR-126 mimic. c: Schematic representation of matching sequence between VCAM1 3’UTR mRNA and miR-126.
d: Luciferase activity of HUVECs transfected with reporter plasmid (VCAM1-pEZX), treated with LAMA84 exosomes and/or contrasfected with
miR-126 inhibitor or miR-126 mimic. For normalization, Renilla luciferase activity was used. Values are the mean ± SD of 3 independent experiments
*p 0.05; **p 0.01.
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endothelial cells
We validated the inhibitory effect of miR-126 on CXCL12
expression at both mRNA and protein level. Real time PCR
analysis demonstrated that the addition of LAMA84 exo-
somes to HUVECs, for 24 hours, caused a dose-dependent
decrease in CXCL12 mRNA (Figure 4a). CXCL12 mRNA
decreased of 60% and 75% in HUVECs treated with 20 and
50 μg/ml of exosomes respectively (Figure 4a). Data were
confirmed, at protein level, by ELISA assay; addition of
LAMA84 exosomes to HUVECs, for 24 h, caused a
dose-dependent decrease in CXCL12 protein in HUVEC
conditioned medium (Figure 4b). The results were also
confirmed by immunofluorescence assays (Figure 4c).
In order to further assess the function of exosomal miR-
126 delivered by LAMA84 exosomes in endothelial cells,
we performed an ELISA assay of conditioned medium of
HUVECs, transfected with an inhibitor or mimic of miR-126, and then treated with different amounts of exosomes.
miR-126 expression was knocked down in HUVECs using
the miR-126 inhibitor (2’-OMe-miR-126), as demonstrated
with real time PCR assay (Additional file 3: Figure S3a).
Inhibition of miR-126 in HUVECs increased the pro-
tein level of CXCL12 in conditioned medium and re-
versed the effects of exosomes treatment (Figure 4d).
On the contrary, the ELISA assay indicated that the
overexpression of miR-126 in HUVECs significantly
decreased CXCL12 protein in conditioned medium
and enhanced the effect of exosomes (Figure 4e). Real
time PCR analysis showed the overexpression effi-
ciency of miR-126, in HUVECs transfected with miR-
126 mimic (Additional file 3: Figure S3b). Our data
indicate that the exosomes treatment induces a dose
and time-dependent regulation of CXCL12 expression
in HUVECs, confirmed by the study of gain and loss
of function for miR-126.
Figure 4 miR-126 shuttled by exosomes modulate CXCL12 expression in HUVECs. a: Real time PCR analysis showed that CXCL12 mRNA
expression decreased in dose-dependent (20 and 50 μg/ml) manner after addition of exosomes to endothelial cells. Values are the mean ± SD of
3 independent experiments **p≤ 0.01. b: CXCL12 protein levels, assessed by ELISA, in HUVEC-conditioned medium obtained after 24 hours of
stimulation with: low serum medium (Control), 20 μg/ml of exosomes (Exo 20 μg/ml) and 50 μg/ml of exosomes (Exo 50 μg/ml). Values are the
mean ± SD of 3 independent experiments **p≤ 0.01. c: Confocal microscopy analyses of HUVECs treated with 50 μg/ml of exosomes for 24 h.
HUVECs were stained with Texas Red-conjugated anti-CXCL12 antibodies, nuclear counterstaining was performed using Hoescht (blue). Scale
bar = 10 μm. d: CXCL12 protein levels, assessed by ELISA, in HUVEC-conditioned medium obtained after 24 hours of stimulation with: low serum
medium (Control), 20 μg/ml of exosomes (Exo 20 μg/ml) and 50 μg/ml of exosomes (Exo 50 μg/ml). CXCL12 protein levels were also evaluated
in HUVECs transfected with miR-126 inhibitor (2-O-Me-miR-126) and treated with: 20 μg/ml of exosomes (Exo 20 μg/ml + 2-Me-miR-126) and
50 μg/ml of exosomes (Exo 50 μg/ml + 2-Me-miR-126). As a negative control, miScript Inhibitor Negative Control (Scramble) was used. e: CXCL12
protein levels were also evaluated in HUVECs transfected with miR-126 mimic and treated with: 20 μg/ml of exosomes (Exo 20 μg/ml +miR-126
mimic) and 50 μg/ml of exosomes (Exo 50 μg/ml + miR-126 mimic). As a negative control of transfection, the AllStars Negative Control (Scramble)
was used.
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In silico analysis identified VCAM1 3’-UTR mRNA as a
target of miR-126; we first evaluated, by real time PCR
analysis, if exosomes treatment of HUVECs induces a
time-dependent modulation of VCAM1 mRNA expres-
sion, As shown in Figure 5a LAMA84 exosomes induce
VCAM1 mRNA expression up to 12 h of treatment, indose dependent manner while there was a decrease in
VCAM1 mRNA levels at later time points suggesting a
time-dependent regulation of VCAM1 expression. In
HUVECs transfected with miR-126 inhibitor (2’-OMe-
miR-126), VCAM1 mRNA expression increased 3 fold
compared with untrasfected cells (Figure 5b). Forced ex-
pression of miR-126 in HUVECs did not affect the rela-
tive amount of VCAM1 mRNA (Figure 5c), indicating
Figure 5 miR-126 shuttled by exosomes modulates VCAM1 expression in HUVECs. a: Real Time PCR analysis showed a time dependent
modulation of VCAM1 mRNA expression after the addition of 10 (10 μg/ml), 20 (20 μg/ml) and 50 μg/ml (50 μg/ml) exosomes to endothelial
cells. b: Real Time PCR analysis of VCAM1 mRNA expression levels in HUVECs transfected with miR-126 inhibitor (2-O-Me-miR-126) compared with
untrasfected HUVECs (Control). c: Real Time PCR analysis of VCAM1 expression levels in HUVECs transfected with miR-126 mimic compared with
untrasfected HUVECs (Control).d: Histogram shows the MFI (mean fluorescence intensity) of surface expression of VCAM1 in HUVECs after 24 hours
of treatment with: low serum medium (Control), 20 μg/ml of exosomes (Exo 20 μg/ml). Surface expression of VCAM1 was evaluated, with FACS
analysis, in HUVECs transfected with miR-126 inhibitor (2-Ome-miR-126) and treated with 20 μg/ml of exosomes (2-Ome-miR-126 + Exo 20 μg/ml).
As a negative control, miScript Inhibitor Negative Control (scramble) was used. Surface expression of VCAM1 was also evaluated in HUVECs
transfected with miR-126 mimic (miR-126 mimic) and treated with 20 μg/ml of exosomes (miR-126 mimic + Exo 20 μg/ml). Values are the mean
± SD of 3 independent experiments *p ≤ 0.05 **p≤ 0.01.
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increase of miR-126 mimic.
FACS analyses indicated that the protein level of
VCAM1 expressed in HUVEC surface decreased after
24 hours of treatment with 20 μg/ml of exosomes
(Figure 5d) compared with control cells. The inhibition of
miR-126 in HUVECs caused an increase of VCAM1
localization on HUVEC surface and reversed the effect of
exosomes (Figure 5d). The treatment with LAMA84 exo-
somes (20 μg/ml) of HUVECs control and transfected
with miR-126 mimic did not further affect VCAM1 pro-
tein expression compared with HUVECs transfected with
miR-126 mimic. It is likely that the small amount of
VCAM1 in the HUVEC surface after treatment with exo-
somes, transporting miR-126, or in HUVECs transfected
with miR-126 mimic does not allow observation of a fur-
ther VCAM1 inhibition. Our data indicate that theexosomes treatment induces a dose and time-dependent
regulation of VCAM1 expression in HUVECs, confimed
by the study of gain and loss of function for miR-126.
miR-126 delivered by exosomes reduces LAMA84 cells
migration
Cell migration is a critical step for many biologic processes
including leukemic blasts mobilization from bone marrow.
We analyzed the effects of conditioned medium (CM)
from HUVECs treated with exosomes (10–50 μg/ml) on
LAMA84 cells motility. Figure 6a shows that LAMA84
cells migration towards HUVEC conditioned medium,
for 24 hours, decreased in a dose dependent manner.
LAMA84 cells were unable to migrate towards HUVEC
conditioned medium in less than 18 hours.
When we used conditioned medium from HUVECs over-
expressing miR-126 (Figure 6a), we observed a decrease in
Figure 6 miR-126 delivered by exosomes modulates LAMA84 migration, adhesion and transendothelial transmigration. a: Effects of
conditioned medium (CM) of HUVECs pretreated with 10 μg/ml 20 μg/ml and 50 μg/ml of exosomes on LAMA84 cells motility compared with
CM from untreated HUVECs. LAMA84 cells motility was determined towards conditioned medium of HUVECs transfected with miR-126 inhibitor
(2’-O-Me-miR-126) and treated with 10 μg/ml (Exo 10μg/ml, 2’-O-Me-miR-126), 20 μg/ml (Exo 20μg/ml, 2’-O-Me-miR-126) and 50 μg/ml (Exo 50
μg/ml, 2’-O-Me-miR-126) of LAMA84 exosomes compared with untransfected cells. MiScript Inhibitor Negative Control (Scramble) was used as a
negative control of miR-126 inhibitor transfection. LAMA84 cells motility towards CM of HUVECs transfected with: miR-126 mimic and treated with
10 μg/ml (Exo 10μg/ml, miR-126 mimic), 20 μg/ml (Exo 20 μg/ml, miR-126 mimic) and 50 μg/ml (Exo 50μg/ml, miR-126 mimic) of LAMA84
exosomes compared with untransfected cells. AllStars Negative Control (Scramble) was used as a negative control of miR-126 mimic transfection.
Values are expressed as Fold of Increase (FOI). Values are the mean ± SD of 5 fields in 3 independent experiments *p 0.05; **p 0.01. b: Adhesion
of LAMA84 cells to HUVECs treated, for 6-12-24 hours, with 20 and 50 μg/ml of LAMA84 exosomes compared with control HUVECs. c: Adhesion
of LAMA84 cells to HUVECs treated with 20 and 50 μg/ml of LAMA84 exosomes compared with control HUVECs. The adhesion of LAMA84 cells
was evaluated on HUVECs transfected with miR-126 mimic and then treated with 20 and 50 μg/ml of LAMA84 exosomes. d: The adhesion of
LAMA84 cells was evaluated in HUVECs transfected with miR-126 inhibitor and then treated with 20 and 50 μg/ml of LAMA84 exosomes. e:
HUVECs were grown as a monolayer and treated with 10, 20, 50 μg/ml of LAMA84 exosomes. After 6-12-24 hours of treatment, we evaluated the
transendothelial migration of LAMA84 cells.
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in HUVECs increased LAMA84 cells migration com-
pared with untransfected cells (Figure 6a). The use of a
CM, from exosome-treated and miR-126 inhibitor-
transfected HUVECs, enhanced the LAMA84 cells motility
compared with untransfected endothelial cells (Figure 6a).
On the contrary, CM from HUVECs, transfected with
miR-126 mimic and treated with LAMA84 exosomes,
showed a slight modulation of LAMA84 cells motility
(Figure 6a), likely because the overexpression of miR-
126 could not be further affected by the amount of
miRNA shuttled by exosomes. These results indicate
that miR-126 transported by LAMA84-exosomes af-
fected LAMA84 cells migration.
miR-126 shuttled by exosomes modulates LAMA84 cells
adhesion on HUVECs
In order to better understand the biological effect of
VCAM1 downregulation, we performed adhesion assays.
To evaluate if exosomes treatment of HUVECs induce a
time-dipendent modulation of LAMA84 cells adhesion on
HUVECs monolayer, we performed a time-course adhe-
sion assay. As show in Figure 6b the adhesion of LAMA84
cells on HUVECs monolayer increased up to 12 h com-
pared with control HUVECs while we observed a de-
creased ability to adhere to endothelial monolayer after
24 h of pretreatment with exosomes.
MiR-126 overexpression in HUVECs decreased the
leukemia cell adhesion (Figure 6c) while the silencing of
miR-126 in HUVECs reversed the effect of exosomes
and restored the adhesion of LAMA84 cells on HUVECs
monolayer (Figure 6d). Additional file 4: Figure S4 shows
the representative fields used for quantification of LAMA84
cells adhesion on the HUVECs monolayer.
Effect of miR-126 shuttled by exosomes on transendothelial
migration of LAMA84 cells
In order to investigate, in an in vitro system, whether
the modulation of CXCL12 and VCAM1 expression by
exosomal miR-126 might play an active role in leukemic
blasts mobilization from the bone marrow, the transen-
dothelial migration assay was performed. HUVECs were
grown as a monolayer and treated with different amount
(10, 20, 50 μg/ml) of LAMA84 exosomes for 6–12 and
24 hours. As shown in Figure 6e, transendothelial migra-
tion of LAMA84 cells toward a complete medium, used
as chemoattractant, decreased when HUVECs were
treated with exosomes for 6 hours and markedly in-
creased when HUVECs were treated with exosomes for
24 hours.
Discussion
It is known that in chronic myelogenous leukemia the
bone marrow microenvironment contributes to diseaseprogression through the establishment of a bi-directional
crosstalk between BM resident cells and cancer cells. This
crosstalk may affect therapy response and CML stem cell
survival [23]. An important component of bone marrow,
in addition to the BM stromal cells (MSC), is represented
by endothelial cells; these cells may provide very import-
ant cues to tumor development and progression. They
form tumor-associated vessels to provide nutritional sup-
port to the growing tumor or may sustain leukemia cell
growth and dissemination through the secretion of cyto-
kines and extracellular matrix components [24].
Our study adds another piece of information in the
complex interaction between the bone marrow micro-
environment and cancer cells by introducing the role of
cancer secreted microvesicles.
Our previous in vitro and in vivo work demonstrated
that LAMA84 cells release exosomes able to induce in
endothelial cells an angiogenic phenotype through the
stimulation of an IL-8 dependent autocrine loop [5-7].
In this study we show that LAMA84 cells may modulate
in vitro gene expression in endothelial cells through the
release of miRNAs contained within exosomes. miRNAs
profiling evidenced a similarity in the miRNA species
found in exosomes and parental cells, however in line
with other reports [25] we show that not all miRNAs
can be incorporated into exosomes thus suggesting a
sorting mechanism, that is still unclear. Our experiments
showed in Figure 1 indicate that exosomes, containing
miRNAs, are incorporated and released through an en-
ergy and ceramide-dependent pathway given that incu-
bation of LAMA84 cells at 4°C or with GW4869
inhibited the transfer of labelled miR-126 into HUVECs.
Of the 124 miRNAs we identified in exosomes, we fo-
cused on miR-126. miR-126 is considered an angioMiR
with an abundant level in highly vascularized tissues,
and is known to regulate many aspects of endothelial
cell biology including cell motility, vasculature integrity,
cell survival and cytoskeletal organization [11]. The in-
volvement of miR-126 in cancer biology is not limited to
modulation of angiogenesis and data in literature indi-
cate that this miRNA plays a role in cancers of the
gastrointestinal tract, breast, lung and other organs by
altering several cellular mechanisms of cancer pathogen-
esis [26]. In myeloid leukemia miR-126 was found to
down-regulate HOXA9, an oncogene encoding a tran-
scription factor that regulates hematopoietic develop-
ment [27], while Cammarata and colleagues found that
miR-126, upregulated in acute myeloid leukemia, in-
duced cell proliferation via the inhibition of PLK, one
member of the Polo-like kinase that regulates the cell
cycle [28]. Our study suggests a different mechanism by
which miR-126 may affect CML development, the alter-
ation of the bone marrow microenvironment due to in-
appropriate cancer cell retention, adhesion and motility.
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components of the bone marrow niche are in part regu-
lated, by miR-126 contained in LAMA84 exosomes.
CXCL12 or SDF-1 is a chemokine that binds specifically
to the G-protein coupled receptor, CXCR4. Sipkins and
colleagues have demonstrated that disruption of the inter-
actions between SDF-1 and its receptor CXCR4 inhibits
the homing of Nalm-6 cells (an acute lymphoblastic leu-
kaemia cell line) to the BM [29]. Our data indicate that
exosomal delivery of miR-126 to endothelial cells de-
creases CXCL12 release from HUVECs and concomitantly
reduces the motility of LAMA84 cells towards HUVEC
conditioned medium. To further study the role of miR-
126 in the modulation of CXCL12 secretion, we used the
inhibitor of miR-126 that can bind and inhibit miR-126
molecules, or its negative control scramble oligomer, to
transfect HUVECs. MiR-126 inhibitor decreased by 45%
the miR-126 expression in the cells and concomitantly
augmented CXCL12 protein level. Consistently with these
data, the overexpression of miR-126 mimic caused a de-
crease of SDF-1 level and lower migration tendency of
LAMA84 cells toward EC conditioned medium. Another
target of miR-126 that may be relevant to CML disease
progression is VCAM1, a cell-cell adhesion molecule.
Experimental studies have demonstrated that miR-126
downregulates VCAM1 expression in endothelial cells
through a post-trascriptional mechanism acting on
mRNA translation [13]. Fish et al. also reported that
VCAM1 mRNA levels were elevated upon miR-126
inhibition, but were not decreased in the presence of
miR-126 mimic thus supporting the hypothesis of a
regulative mechanism at translational level [12]. More-
over, it was demonstrated that forced expression of
miR-126 in the Lin− bone marrow cells induced min-
imal change in the relative levels of VCAM1 mRNA but
caused a decrease in the proportion of surface VCAM1-
positive Sca-1hi cKithi cells within this population [30].
From a functional point of view, a recent report from
Salvucci and colleagues reported that miR-126 con-
tained in G-CSF-mobilized vesicles in the bone marrow
induced hematopoietic stem/progenitor cell (HSPC)
mobilization by reducing the expression of VCAM1 in
HSPC endothelial cells and other non-hematopoietic
cells [30]. We found that VCAM1 expression is de-
creased following incubation of endothelial cells with
LAMA84 exosomes and that this effect was due to miR-
126 contained in the nanovesicles (Figure 5). This effect
was partially reduced by the introduction of miR-126 in-
hibitor in HUVECs (Figure 5). As a functional conse-
quence of the diminished amount of VCAM1 in EC, the
adhesion of LAMA84 to HUVECs was reduced after
exosome treatment. In our previous study, we demon-
strated that the treatment of endothelial cells with exo-
somes for short times (6 h), induced VCAM1 at boththe mRNA and protein level and increased adhesion of
LAMA84 cells on the HUVECs monolayer [7].
In this new study, we found that the treatment of
endothelial cells with exosomes for 24 hours downregu-
lated VCAM1 mRNA and protein expression and caused
a decrease of LAMA84 adhesion cells on the HUVECs
monolayer. In order to explain these apparently contrast-
ing results, we hypothesize that in the first 6 hours, the
exosomes treatment of HUVECs induces the expression
of VCAM1 to allow the adhesion of the cancer cells on
the endothelium, as the first step of cells migration.
After a longer time of HUVECs exposure to exosomes,
LAMA84 cells lose the ability to adhere on the endothe-
lial cells and increase their capacity to migrate towards
a richer source of chemoattractants.
The downregulation of CXCL12 and VCAM1 by miR-
126 and their upregulation when the miRNAs are knocked
down suggests that these miRNA are deeply involved in
the regulation of these two proteins. CXCL12 is a chemo-
kine abundantly produced by the bone marrow micro-
environment, and its receptor CXCR4 has crucial roles in
malignant cell trafficking [31,32]. We demonstrated with
an in vitro transendothelial cell migration assay that the
treatment of HUVECs with LAMA84 exosomes induces
LAMA84 migration through endothelial monolayer,
likely due to a decrease of VCAM1-mediated adhesion
of leukemia cells to EC and a concomitant chemotaxis
toward serum.
Conclusion
Our results indicate a complex exosome-mediated cross-
talk potentially occurring in the bone marrow microenvir-
onment that may facilitate the exit of LAMA84 cells from
the bone marrow and their dissemination in the body at
least partly via delivery of miR-126.
Material and methods
Cell culture and reagents
HUVECs were obtained from Lonza (Verviers, Belgium)
and grown in endothelial growth medium (EGM, bullet
kit, Lonza) according to supplier’s information. LAMA84,
(DMSZ Germany) chronic myelogenous leukemia cells,
were cultured in RPMI 1640 medium (Euroclone, UK) sup-
plemented with 10% fetal bovine serum (Euroclone, UK),
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin (Euroclone, UK). All other reagents were
purchased from Sigma (St. Louis, MO), if not otherwise
cited.
Exosomes isolation
Exosomes released by LAMA84 cells during a 24 h culture
period, were isolated from conditioned culture medium
supplemented with 10% FBS (previously ultracentrifuged)
by different centrifugations as previously described [7] and
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ion. Vesicles contained in the sucrose cushion were recov-
ered, washed, ultracentrifuged for 90 min in PBS and
collected for use. Exosome protein content was determined
by the Bradford method.
TaqMan Human MicroRNA Array for Profiling of miRNAs
Total cellular RNA and miRNAs were isolated from
LAMA84 cells and exosomes using the RNAspin Mini
(GE Healthcare Science, Uppsala, Sweden) and analysed
through 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). 600 ng of total RNA was reverse tran-
scribed using Megaplex™ RT Primers Human Pool A
(Life Technologies, Carlsbad, California, U.S.) according
to manufacturer’s instructions. Conditions for the re-
verse transcription reaction were as follows: 16°C for
2 minutes, 42°C for 1 minute, 50°C for 1 second for
40 cycles, 85°C for 5 minutes then hold at 4°C. Obtained
cDNA was diluted, mixed with TaqMan Gene Expression
Master Mix and loaded into each of the eight fill ports
on the TaqMan® Human MicroRNA Array A (Life Tech-
nologies, Carlsbad, California, U.S.). The array was cen-
trifuged at 1200 rpm twice for 1 minute each and then
run on ABI-PRISM 7900 HT Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA) using
the manufacturer’s recommended program. Data were
quantified using the SDS 2.1 software and normalized
using the miR-18b as endogenous control or RNU6-2.
The cycle threshold (Ct) value, which was calculated
relatively to the endogenous control, was used for our
analysis (ΔCt). The 2-ΔΔCT (delta-delta-Ct algorithm)
method was used to calculate the relative changes in
gene expression.
Quantitative polymerase chain reaction (qPCR) for
miRNAs and pre-miRNAs
The expression of miR-126 was validated by miScript
PCR System (QIAGEN, Hilden, Germany). Reverse tran-
scription reactions were performed using miScript II RT
Kit (QIAGEN, Hilden, Germany) as described by the
manufacturer’s instructions. We used miScript HiSpec
Buffer for cDNA synthesis to detect mature miRNA and
miScript HiFlex Buffer for cDNA synthesis to enable
quantification of precursor miRNA, Quantitative Real
Time PCR was performed using miScript SYBR Green
PCR Kit (QIAGEN, Hilden, Germany). Mature miR-126
was detected by miScript Primer Assay and precursor
miR-126 by miScript Precursor Assays according to
manufacturer’s instructions. RNU6-2 was used as endogen-
ous control. Expression levels of miRNAs and pre-miRNA
were determined using the comparative Ct method to
calculate changes in Ct and ultimately fold and percent
change. An average Ct value for each RNA was obtained
for replicate reactions.qPCR for CXCL12 and VCAM1
For CXCL12 and VCAM1 mRNA detection, 1 μg of
total RNA were reverse transcribed using the High Cap-
acity cDNA Archive kit (Life Technologies, Carlsbad,
California, U.S.), according to manufacturer’s instruc-
tions. VCAM1 and CXCL12 transcript levels were mea-
sured by TaqMan Real Time PCR using TaqMan gene
expression assay for VCAM1 (Hs00174239_m1) and for
CXCL12 (Hs00171022_m1) (Life Technologies, Carls-
bad, California, U.S.). Data were analysed as previously
described [7]. Changes in the target mRNA content rela-
tive to GAPDH were determined using the comparative
Ct method as described in the previous paragraph.
HUVECs transfection with miR-126 mimic or inhibitor
Transfection with miScript miR-126 inhibitor (QIAGEN,
Hilden, Germany) or miScript miR-126 mimic (QIA-
GEN, Hilden, Germany) was performed according Fast-
Forward Transfection protocol (QIAGEN, Hilden,
Germany). 6 × 104 HUVECs per well were seed of a 24-
well plate in 500 μl of EGM (Lonza Vervier, Belgium).
miR-126 inhibitor (2’-O-Me-miR-126) or miR-126 mimic
(2 μM) were diluted in 100 μl culture medium without
serum to obtain a final 5 nM miRNA concentration.
The cells were transfected using HiPerFect Transfection
Reagent (QIAGEN, Hilden, Germany) according to manu-
facturer’s instructions for 18 hours. miScript Inhibitor
Negative Control (QIAGEN, Hilden, Germany) and
AllStars Negative Control siRNA (QIAGEN, Hilden,
Germany) was used as negative control as indicated by
manufacture’s technical specifications. Transfection effi-
ciency was evaluated by quantitative Real Time PCR.
Luciferase Activity Assay
The 3’-UTRs of CXCL12 and VCAM1 were cloned in
pEZX-MT01 vector (Genecopoeia, Rockville, MD USA).
The constructs were designed based on the sequence of
miR-126 binding sites. 8x 104 HUVECs per well in a 24-
well plate were seeded in 500 μl of an appropriate cul-
ture medium, the cells were transfected with 300 ng of
the pEZX-MT01 firefly luciferase report diluted in 60 μl
culture medium without serum. HUVECs were co-
trasfected with 6 pmol miR-126 mimic or miR-126 inhibi-
tor using Attractene Transfection Reagent (QIAGEN,
Hilden, Germany) according to manufacturer’s protocol.
To test whether exosomal miR-126 targets CXCL12 and
VCAM1 mRNAs, HUVECs were incubated with 50 μg/ml
of LAMA84 exosomes after the transfection with pEZX-
MT01 vector. Firefly and Renilla Luciferase activities
were measured consecutively using the kit Dual Glo®
Luciferase Assay System (Promega Corp., Madison, WI,
USA) 24 hours after transfection using GloMax®-Multi
Detection System (Promega Corp., Madison, WI, USA).
Each transfection was repeated three times in duplicate.
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Renilla/Firefly Luciferase activities.
Immunofluorescence analysis
HUVEC monolayers were grown to confluence on cover-
slips coated with type I collagen (Calbiochem, Darmstadt,
Germany) and were treated with 50 μg/ml of LAMA84
exosomes or low serum medium for 24 hours. After incu-
bation, cells were processed as previously described [7].
Antibodies used in the experiments were anti-CXCL12
(1:100; Cell Signaling Technologies). Cells were stained
with Texas Red-conjugated secondary anti mouse anti-
bodies (1:100; Molecular Probe, Eugene, OR) and analysed
by confocal microscopy (Leica TSC SP8).
Uptake of LAMA84 exosomes by HUVECs
LAMA84 exosomes were labeled with PKH26 according
to supplier’s information. Briefly, exosomes collected
after the 100,000 × g ultracentrifugation, were incubated
with PKH26 for 10 min at room temperature. Labeled
exosomes were washed in PBS by ultracentrifugation,
the pellets were resuspended in low serum medium and
incubated with HUVECs for 1- 4 hours at 4 or 37°C.
HUVECs were grown on coverslips coated with type I
collagen (Calbiochem, Darmstadt, Germany) and were
treated with increasing doses of LAMA84 exosomes or
low serum medium. In a set of experiments, HUVECs
were pretreated with 50 μM 5-ethyl-N-isopropyl amilor-
ide (EIPA), an known inhibitor of exosomes uptake, for
1 hour. After incubation, cells were processed as previ-
ously described [7]. HUVECs were stained with Alexa
Fluor 633® phalloidin (Molecular Probes, Life Technolo-
gies, Carlsbad, California, U.S) that binds F-actin with
high affinity. Nuclei were stained with Hoechst (Molecu-
lar Probes, Life Technologies, Carlsbad, California, U.S)
and analysed by confocal microscopy (Leica TSC SP8).
Each picture was acquired with laser intensities and
amplifier gains adjusted to avoid pixel saturation. Each
fluorophore used was excited independently and sequen-
tial detection was performed. Each picture consisted of a
z-series of images of 1024–1024 pixel resolution. The
semi-quantitative analysis of fluorescence intensity was
performed using IMAGE-J software (http://imagej.nih.
gov/ij/). We selected the perinuclear area in a section at
5 μm and measured the fluorescence intensity. Values are
the mean ± SD of 15 measurements from three independ-
ent experiments.
Shuttling assays for Cy3-labeled-miRNA precursor
miR-126 precursor (QIAGEN, Hilden, Germany) was la-
beled with Label IT siRNA Tracker Cy3 Kit, according to
the manufacturer’s instructions (Mirus, Madison, WI, USA).
LAMA84 cells (6 x 104) were transfected with 10 nM of
Cy3-labeled pre-miR-126 using HiPerFect TransfectionReagent (QIAGEN, Hilden, Germany) (LAMA84/Cy3-
miR-126). The day after transfection, cells were seeded on
transwells, 3 μm pore filters in cocolture with HUVECs
over night. LAMA84 cells did not migrate through the
3 μm pore filters through 18 h (data not shown).
HUVECs were stained with Hoechst and analysed by
confocal microscopy.
Inhibition of exosome release
LAMA84 cells, transfected with Cy3-labeled pre-miR-
126, were seeded in the upper wells of transwells and in-
cubated with 1 and 5 μM GW4869; in the bottom wells
were plated endothelial cells. After incubation for 18 hours,
the cells were processed as previously described [7] and fi-
nally stained with Hoechst and analyzed by confocal
microscopy.
Adhesion assay
Adhesion assays were performed as previously described
[33]. Briefly HUVECs transfected or not with miR-126
mimic, miR-126 inhibitor or scramble controls, were
grown as a monolayer and incubated for 24 hours with
indicated conditions. After treatment, cells were washed
with PBS and LAMA84 cells were added for 2 hours at
37°C. Adherent cells were stained with hematoxylin/
eosin, each test group was assayed in triplicate; five high
power (400x) fields were counted for each condition.
ELISA for CXCL12
Conditioned medium (CM) of HUVEC, transfected or not
with miR-126 mimic or inhibitor, was collected from cells
stimulated for 24 hours with different amount of LAMA84
exosomes. CM aliquots were centrifuged to remove cellu-
lar debris and CXCL12 protein concentrations were quan-
tified using an ELISA kit (R&D Systems, Minneapolis),
according to the manufacturer’s protocol.
Motility assay
HUVECs transfected or not with miR-126 mimic, miR-126
inhibitor or scramble controls, were grown as a monolayer
and incubated for 24 h with different amount of exosomes.
After treatment, conditioned medium was collected, CM
aliquots were centrifuged to remove cellular debris and
used as chemoattractant. LAMA84 cells were suspended
in serum-free RPMI 1640 medium supplemented with
0.1% BSA in transwells with 8 μm pore filters and exposed
to chemoattractants, for 18 hours. After incubation cells
migrated in the bottom wells were counted.
Transendothelial migration
HUVECs were grown as a monolayer in the upper well of
transwells coated with type I collagen, with 8 μm pore
filter and incubated with LAMA84 exosomes (10–50
μg/ml). After incubation for 18 hours, LAMA84 cells were
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other 18 hours by counting the LAMA84 cells in the
bottom well.
FACS analyses
Expression of HUVEC cell surface VCAM1 was deter-
mined by flow cytometry analysis. HUVECs transfected
or not with miR-126 mimic or inhibitor were incubated
over night with 20 μg/ml of LAMA84-exosomes in a
low serum medium (EGM:RPMI, 1:9). 1 x106 cells were
washed in PBS and incubated with anti-VCAM1-PE
antibody (20 μl) (BD Bioscences, Mountain View, CA,
USA) for 15 min at 4°C according to manufacturer’s rec-
ommendations. Isotype-matched irrelevant antibodies
were used as a negative control. Viable cells were gated
by forward and side scatter and analysis was performed
on 100,000 acquired events for each sample. Samples
were analysed on a FACS Calibur with the use of the
CellQuest software (BD Biosciences, NJ, USA).
Additional files
Additional file 1: Figure S1. a: Semi-quantitative analysis of PKH-26
fluorescence intensity in the cytoplasm of HUVECs treated with 20 μg/ml
and 50 μg/ml of LAMA84-exosomes compared with control cells. HUVECs
were incubated at 37°C, for 1 hour and 4 hours. Black bar shows HUVECs
treated with 50 μg/ml of exosomes and 50 μM EIPA and incubated at
37°C, for 1 hour. Values are the mean ± SD of 15 measurements from 3
independent experiments *p ≤ 0.05.
Additional file 2: Figure S2. LAMA84 exosomes transport miRNAs. a:
Pie chart representation of 200 miRNAs identified by miRNAs expression
profile: 76 miRNAs were only expressed in LAMA84 cells (38%), 18
miRNAs were exclusively expressed in LAMA84 exosomes (9%) and 106
miRNAs were differentially expressed between LAMA84 exosomes and
LAMA84 cells (53%). b: Heat map analysis showing miRNAs differentially
expressed between LAMA84 exosomes and LAMA84 cells. Each row
represents the expression levels for a single miRNA tested in LAMA84
cells and LAMA84 exosomes. Each column shows the expression levels
for the miRNAs tested in LAMA84 cells (left column) and LAMA84
exosomes (right column). The color scale bar on the top indicates Ct
values that correlated to an increase (green) or decrease (red) in the
level of miRNA expression. Black boxes indicate intermediate expression
values. c: miR-126 expression in LAMA84 exosomes and LAMA84 cells.
The real time PCR analysis shows that miR-126 is upregulated in LAMA84
exosomes. The data showed in the graph are expressed as FOI (fold of
increase) and calculated as 2-ΔΔCt. Values are the mean ± SD of 3 independent
experiments *p ≤ 0.05. d: Semi-quantitative analysis of miR-126/Cy3
fluorescence intensity in the cytoplasm of HUVECs co-cultured with
LAMA84/Cy3-miR-126 cells compared to HUVECs co-cultured with
untrasfected LAMA84. Values are the mean ± SD of 15 measurements
from three independent experiments *p ≤ 0.05.
Additional file 3: Figure S3. a: Real Time PCR analysis of miR-126
expression levels in HUVECs transfected with miR-126 inhibitor (2-O-
Me-miR-126) compared with untrasfected HUVECs (control). Values are
the mean ± SD of 3 independent experiments *p ≤ 0.05. b: Real Time PCR
analysis of miR-126 expression levels in HUVECs transfected with miR-126
mimic (miR-126 mimic) compared to untrasfected HUVECs (control).
Values are the mean ± SD of 3 independent experiments **p≤ 0.01.
Additional file 4: Figure S4. Representative fields used for
quantification of the LAMA84 cell adhesion. In this figure the LAMA84
cells adhering to HUVECs treated with 50 μg/ml (Exo 50 μg/ml) of
LAMA84 exosomes compared with control HUVECs (control) areillustrated. The adhesion of LAMA84 cells was also evaluated in HUVECs:
transfected with miR-126 inhibitor (2’-O-Me-miR-126) and HUVEC treated
with 50 μg/ml (Exo 50 μg/ml + 2’-O-Me-miR-126) of LAMA84; transfected
with miR-126 mimic (mirR-126-Mimic) and treated with 50 μg/ml (Exo 50
μg/ml, miR-126 mimic) of LAMA84 exosomes.
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